Moderna's Combination COVID and Flu Vaccine

This chapter explores Moderna's development of a combination COVID and flu vaccine, its promising early-stage trial results, and the challenges of managing multiple respiratory vaccines. It also discusses the decline in Moderna's stock price, investors' concerns about sales, and the potential factors that could reignite interest in the stock.